GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, wherein the British drugmaker beat estimates for both earnings and sales. The ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall ...

GSK PLC GSK +1.87% shares rose 4.74% to £18.55 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX -0.28% rising 0.44% to 10,697.57.

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

GSK stock rose 0.4% after Berenberg upgraded to buy with a £22 target and GSK announced a $750M deal with Chimagen Biosciences for a multiple myeloma asset.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth at the upper end of the guidance ranges. However, it's hard to make a Buy case for it anymore as ...